Nathan Sailor, DO
Family Medicine · Traverse City, MINPI 1194017160
Payments from drug & device makers
Across 131 payments — averaging $124.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$13K
- AbbVie$657
- Braeburn Inc.$295
- GSK$262
- Johnson & Johnson$245
- AstraZeneca$223
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$12,22875%
- Travel & lodging$4873%
- Food & beverage$3,58422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $13,094 |
| AbbVie(2 entities) | 38 | $657 |
| Braeburn Inc. | 4 | $295 |
| GSK | 10 | $262 |
| Johnson & Johnson | 4 | $245 |
| AstraZeneca | 6 | $223 |
| Nevro Corp. | 2 | $172 |
| Boehringer Ingelheim | 7 | $166 |
| Cardiovascular Systems Inc. | 2 | $154 |
| Alkermes, Inc. | 3 | $137 |
| Bard Peripheral Vascular, Inc. | 1 | $104 |
| Globus Medical | 1 | $94 |
| Bayer | 5 | $91 |
| Inari Medical, Inc. | 2 | $79 |
| Amgen | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Pfizer | 3 | $51 |
| Astellas Pharma US Inc | 2 | $37 |
| Mylan Specialty L.p. | 2 | $37 |
| Lilly USA, LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Vertex | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Exact Sciences | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$12,934
- BRIXADI$263
- SPRAVATO$182
- Senza$128
- TRELEGY ELLIPTA$120
- VRAYLAR$110
- Lutonix Drug Coated Balloon$104
- VIVITROL$104
How this compares
$16,300 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 100 | $143,090 |
| TrulicityDulaglutide | 110 | $139,462 |
| EliquisApixaban | 88 | $94,539 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $86,654 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $65,996 |
| MounjaroTirzepatide | 53 | $65,164 |
| OzempicSemaglutide | 37 | $44,431 |
| FarxigaDapagliflozin Propanediol | 30 | $37,834 |
| XareltoRivaroxaban | 27 | $32,731 |
| RybelsusSemaglutide | 16 | $23,038 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 48 | $9,854 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 29 | $8,671 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 67 | $6,796 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $4,685 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $34 | $204,626163 claims |
| Boehringer IngelheimJardiance | $166 | $143,090100 claims |
| PfizerEliquis, Abrysvo | $51 | $103,210117 claims |
| GSKTrelegy Ellipta, Shingrix | $262 | $75,84999 claims |
| Novo NordiskOzempic, Rybelsus | $13,094 | $67,46953 claims |
| AstraZenecaFarxiga, Symbicort | $223 | $42,47349 claims |
| Johnson & JohnsonXarelto | $245 | $32,73127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Traverse City
- Rafay BaigTraverse City$48K
- Kathryn ShafferTraverse City$20K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.